

Jasleen K Sodhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/568325/publications.pdf>

Version: 2024-02-01

34
papers

495
citations

686830

13
h-index

713013

21
g-index

34
all docs

34
docs citations

34
times ranked

472
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Reaction Mediated by Human Aldehyde Oxidase: Amide Hydrolysis of GDC-0834. Drug Metabolism and Disposition, 2015, 43, 908-915.	1.7	53
2	Association of CYP2C9*2 With Bosentan-Induced Liver Injury. Clinical Pharmacology and Therapeutics, 2013, 94, 678-686.	2.3	49
3	Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3531-3538.	1.0	38
4	Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. Journal of Medicinal Chemistry, 2021, 64, 3546-3559.	2.9	29
5	Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?. Drug Metabolism and Disposition, 2020, 48, 537-543.	1.7	25
6	Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 8345-8368.	2.9	24
7	How Transporters Have Changed Basic Pharmacokinetic Understanding. AAPS Journal, 2019, 21, 103.	2.2	22
8	Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 155-163.	0.8	21
9	Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. AAPS Journal, 2020, 22, 120.	2.2	21
10	The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. Pharmaceutical Research, 2018, 35, 242.	1.7	19
11	Pharmacogenomics in the era of next generation sequencing - from byte to bedside. Drug Metabolism Reviews, 2021, 53, 253-278.	1.5	19
12	There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions. AAPS Journal, 2021, 23, 67.	2.2	19
13	Can <i>In Vitro</i> - <i>In Vivo</i> Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions. Clinical Pharmacology and Therapeutics, 2022, 111, 1022-1035.	2.3	16
14	Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. Drug Metabolism Reviews, 2015, 47, 291-319.	1.5	15
15	Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition. Pharmaceutical Research, 2020, 37, 208.	1.7	15
16	Recent developments in <i>in vitro</i> and <i>in vivo</i> models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. Drug Metabolism Reviews, 2021, 53, 207-233.	1.5	15
17	1-Aminobenzotriazole Coincubated with (S)-Warfarin Results in Potent Inactivation of CYP2C9. Drug Metabolism and Disposition, 2014, 42, 813-817.	1.7	12
18	Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. Clinical Pharmacokinetics, 2021, 60, 205-222.	1.6	11

#	ARTICLE	IF	CITATIONS
19	The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. <i>AAPS Journal</i> , 2020, 22, 111.	2.2	10
20	Advances in the study of drug metabolism – symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX). <i>Drug Metabolism Reviews</i> , 2020, 52, 395-407.	1.5	8
21	A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 306-315.	2.3	8
22	Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1553.	1.8	6
23	Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (K _{puu}) on Prediction of Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2020, 37, 73.	1.7	6
24	The Effects of Drug Metabolizing Enzyme Inhibitors on Hepatic Efflux and Uptake Transporters. <i>Drug Metabolism Letters</i> , 2018, 11, 111-118.	0.5	6
25	For a series of methylindole analogs, reactive metabolite formation is a poor predictor of intrinsic cytotoxicity in human hepatocytes. <i>Toxicology Research</i> , 2014, 3, 184.	0.9	5
26	Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption. <i>Pharmaceutical Research</i> , 2021, 38, 795-801.	1.7	5
27	Recent developments in predicting CYP-independent metabolism. <i>Drug Metabolism Reviews</i> , 2021, 53, 188-206.	1.5	5
28	Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. <i>Pharmaceutical Research</i> , 2021, 38, 1639-1644.	1.7	3
29	Does Addition of Protein to Hepatocyte or Microsomal In Vitro Incubations Provide a Useful Improvement in In Vitro-In Vivo Extrapolation Predictability?. <i>Drug Metabolism and Disposition</i> , 2022, 50, 401-412.	1.7	3
30	Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT). <i>Methods in Molecular Biology</i> , 2021, 2342, 765-779.	0.4	2
31	Recent advances in computational metabolite structure predictions and altered metabolic pathways assessment to inform drug development processes. <i>Drug Metabolism Reviews</i> , 2021, 53, 173-187.	1.5	2
32	Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 480-485.	2.3	2
33	International Society for the Study of Xenobiotics (ISSX) New Investigator Group Committee 2019-2020 concluding remarks. <i>Drug Metabolism Reviews</i> , 2021, 53, 1-6.	1.5	1
34	Impact of hepatic drug distribution on predictions of clearance. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, S23.	1.1	0